BioCardia, Inc. (BCDA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, BioCardia reported revenue of $0, down 100.0% from $58,000 the year before. Net income was -$8.2M. Operating activities generated -$7.4M of cash, leaving -$7.4M of free cash flow. At fiscal year end, BioCardia held $3.4M in total assets against $2.5M in total liabilities, including $2.5M of cash and equivalents.
Open the full interactive BioCardia financials → Quarterly statements, key ratios, valuation history and price charts.
BioCardia Key Stats
| Share Price | $0.99 |
|---|---|
| Market Cap | $12.0M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $0.77 – $1.56 |
| Shares Outstanding | 12.1 million (basic, 2026 Q2) |
BioCardia Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $145,000 | $1.0M | $1.4M | $477,000 | $58,000 | $0 |
| Cost of Goods Sold | $4,000 | $0 | — | — | — | — |
| Gross Profit | $141,000 | $1.0M | — | — | — | — |
| Operating Income | -$15.5M | -$12.6M | -$11.9M | -$11.6M | -$8.0M | -$8.3M |
| Pre-Tax Income | -$15.0M | -$12.6M | -$11.9M | -$11.6M | -$7.9M | -$8.2M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$15.0M | -$12.6M | -$11.9M | -$11.6M | -$7.9M | -$8.2M |
| Diluted EPS | -$22.20 | -$11.25 | — | — | — | — |
BioCardia Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.5M | -$2.0M | -$2.3M | -$1.6M |
| Diluted EPS | — | — | -$0.21 | — |
BioCardia Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.4M | $12.9M | $7.4M | $1.1M | $2.4M | $2.5M |
| Current Assets | $22.7M | $13.5M | $7.9M | $1.5M | $2.6M | $2.7M |
| Total Assets | $23.4M | $15.7M | $9.8M | $3.0M | $3.7M | $3.4M |
| Current Liabilities | $4.2M | $3.7M | $3.6M | $3.6M | $2.3M | $2.4M |
| Total Liabilities | $4.2M | $5.3M | $4.9M | $4.6M | $2.9M | $2.5M |
| Shareholders' Equity | $19.2M | $10.4M | $4.9M | -$1.6M | $837,000 | $895,000 |
BioCardia Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$12.4M | -$10.4M | -$10.6M | -$10.0M | -$8.0M | -$7.4M |
| Cash From Investing | -$32,000 | -$116,000 | -$70,000 | -$12,000 | -$6,000 | -$7,000 |
| Cash From Financing | $28.2M | $1.9M | $5.1M | $3.7M | $9.3M | $7.6M |
| Free Cash Flow | -$12.4M | -$10.5M | -$10.6M | -$10.0M | -$8.0M | -$7.4M |
Figures from BioCardia's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full BioCardia financials page for every line item.
BioCardia Company Profile
| Ticker | BCDA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Sunnyvale, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000925741 |
Frequently Asked Questions
What was BioCardia's revenue in fiscal 2025?
BioCardia (BCDA) reported revenue of $0 for fiscal 2025.
What is BioCardia's annual revenue history?
BioCardia's annual revenue by fiscal year: 2020: $145,000; 2021: $1.0M; 2022: $1.4M; 2023: $477,000; 2024: $58,000; 2025: $0.
What was BioCardia's net income in fiscal 2025?
BioCardia reported net income of -$8.2M for fiscal 2025.
How much free cash flow did BioCardia generate in fiscal 2025?
BioCardia generated -$7.4M of free cash flow in fiscal 2025.
What was BioCardia's revenue last quarter?
In its most recent reported quarter (2026 Q2), BioCardia reported revenue of $0.
How many shares of BioCardia are outstanding?
BioCardia reported a weighted average of 12.1 million basic shares outstanding in 2026 Q2.
What is BioCardia's market cap?
Based on its latest closing price, BioCardia (BCDA) has a market capitalization of about $12.0M.
When does BioCardia's fiscal year end?
BioCardia's fiscal year end, as registered with the SEC, is December 31.
Where is BioCardia headquartered?
BioCardia lists its business address in Sunnyvale, California in its SEC filings.
BioCardia Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →